CANF Panoramica delle azioni Can-Fite BioPharma Ltd., una società biofarmaceutica in fase clinica, sviluppa in Israele prodotti terapeutici a base di piccole molecole biodisponibili per via orale per il trattamento del cancro, delle malattie infiammatorie del fegato e della disfunzione erettile. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Can-Fite BioPharma Ltd. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Can-Fite BioPharma Prezzi storici delle azioni Prezzo attuale dell'azione ₪0.02 Massimo di 52 settimane ₪0.056 Minimo di 52 settimane ₪0.017 Beta 0.46 Variazione di 1 mese 11.11% Variazione a 3 mesi -39.39% Variazione di 1 anno -23.08% Variazione a 3 anni -85.19% Variazione a 5 anni -93.33% Variazione dall'IPO -99.94%
Notizie e aggiornamenti recenti
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson Dec 30
New major risk - Market cap size Dec 27
Can-Fite Biopharma Ltd. Announces 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug Dec 04
Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Nov 12
Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson Oct 18
Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma Sep 16 Vedi altri aggiornamenti
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson Dec 30
New major risk - Market cap size Dec 27
Can-Fite Biopharma Ltd. Announces 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug Dec 04
Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Nov 12
Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson Oct 18
Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma Sep 16
New major risk - Shareholder dilution Sep 15
Insufficient new directors Sep 01
First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023) Aug 31
Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson Jul 01
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix Jun 29
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver Jun 24
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year Jun 19
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study Jun 13
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study Jun 06
Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024 May 25
New minor risk - Share price stability May 19
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study May 11
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 May 08
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration (Fda) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study Apr 03
No longer forecast to breakeven Apr 02
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Mar 31
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action Dec 21
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson Dec 19
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients Dec 05
Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022) Dec 02
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson Nov 22
Can-Fite Biopharma Ltd. Provides Business Update Nov 02
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal Oct 31
New minor risk - Share price stability Oct 23
New major risk - Market cap size Oct 08
New major risk - Financial data availability Sep 05
First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022) Sep 02
Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome Aug 25
Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis Aug 19
New major risk - Revenue and earnings growth Jul 25
No longer forecast to breakeven Jul 25
Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan Jun 30
Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023 Jun 24
Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson Jun 14
First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022) Jun 03
Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 01
No longer forecast to breakeven Apr 01
No longer forecast to breakeven Mar 30
Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania Feb 16
Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021) Feb 04
Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies Jan 25
Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow Jan 11
Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma Dec 29
Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021) Nov 26
Insufficient new directors Nov 16
Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology Sep 13
Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021) Aug 27
Forecast to breakeven in 2023 Aug 26
Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania Aug 24
Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix Aug 18
Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022 Jul 28
Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis Jul 12
Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis Jun 30
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth? Jun 30
First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021) May 28
Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel May 18
Insufficient new directors Apr 27
Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate Apr 06 Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022 Mar 10
We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate Mar 08
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson Feb 01
Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans Jan 14
Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors Dec 30
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Dec 21
Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January Dec 08
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Nov 27
Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis Nov 24
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans? Nov 21
Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study Sep 03
Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020) Aug 28
Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment Jun 17
No longer forecast to breakeven Jun 16
Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson Jun 03
Can-Fite BioPharma Ltd. Provides Clinical Update May 28
First quarter 2021 earnings released: US$0.004 loss per share (vs US$0.025 loss in 1Q 2020) May 28
No longer forecast to breakeven May 28
Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely May 16
Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study Apr 30
Full year 2020 earnings released: US$0.04 loss per share (vs US$0.11 loss in FY 2019) Mar 27
Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model Mar 19
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol Mar 06
Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study Feb 23
New 90-day high: ₪0.31 Feb 22
New 90-day high: ₪0.24 Feb 03
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies Feb 02
We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate Jan 31
Can-Fite BioPharma Ltd Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers Jan 09
Can-Fite Biopharma Ltd. Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs Dec 17
Can-Fite BioPharma Ltd. Announces Namodenoson Drug Candidate for Non-Alcoholic Steatohepatitis Treatment Dec 15
Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020 Dec 03 Rendimenti per gli azionisti CANF IL Biotechs IL Mercato 7D 0% -4.6% 3.1% 1Y -23.1% -20.2% 32.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: CANF ha avuto una performance inferiore rispetto al IL Biotechs che ha registrato un rendimento -20.2 % nell'ultimo anno.
Rendimento vs Mercato: CANF ha avuto una performance inferiore al mercato IL che ha registrato un rendimento 32.4 % nell'ultimo anno.
Volatilità dei prezzi Is CANF's price volatile compared to industry and market? CANF volatility CANF Average Weekly Movement 10.7% Biotechs Industry Average Movement 10.7% Market Average Movement 4.4% 10% most volatile stocks in IL Market 8.9% 10% least volatile stocks in IL Market 3.1%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di CANF è stato volatile rispetto al mercato IL.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di CANF è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni IL.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1994 8 Motti Farbstein www.canfite.com
Can-Fite BioPharma Ltd., una società biofarmaceutica in fase clinica, sviluppa prodotti terapeutici a base di piccole molecole biodisponibili per via orale per il trattamento del cancro, delle malattie infiammatorie del fegato e della disfunzione erettile in Israele. Il candidato farmaco principale dell'azienda, Piclidenoson, ha completato la sperimentazione clinica di Fase III per il trattamento della psoriasi. L'azienda sviluppa Namodenoson, che è in fase di sperimentazione clinica di Fase III per il trattamento del cancro al fegato e di Fase IIa per il trattamento del cancro al pancreas, nonché in fase di sperimentazione di Fase IIb per il trattamento della steatoepatite associata al metabolismo, e CF602, che è in fase di sperimentazione preclinica per il trattamento della disfunzione erettile.
Mostra di più Can-Fite BioPharma Ltd. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Can-Fite BioPharma con la sua capitalizzazione di mercato? CANF statistiche fondamentali Capitalizzazione di mercato ₪59.82m Guadagni(TTM ) -₪26.28m Ricavi(TTM ) ₪2.38m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) CANF Conto economico (TTM ) Ricavi US$667.00k Costo del fatturato US$0 Profitto lordo US$667.00k Altre spese US$8.04m Guadagni -US$7.37m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.0025 Margine lordo 100.00% Margine di profitto netto -1,105.10% Rapporto debito/patrimonio netto 0%
Come si è comportato CANF nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/19 08:54 Prezzo dell'azione a fine giornata 2025/01/16 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Can-Fite BioPharma Ltd. è coperta da 9 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione null null CG Capital Jason Kolbert D. Boral Capital LLC. Deepak Sonawane Haitong International Research Limited
Mostra 6 altri analisti 
